3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Glioblastoma
41
Glioma
22
Brain Neoplasms
14
Astrocytoma
11
Neuroblastoma
10
Gliosarcoma
10
Neoplasms
8
Sarcoma, Ewing
7
Rhabdomyosarcoma
6
Sarcoma
5
Recurrence
5
Oligodendroglioma
5
Medulloblastoma
4
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Diffuse Intrinsic Pontine Glioma
3
Wilms Tumor
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Melanoma
2
Lymphoma, Follicular
2
Hepatoblastoma
2
Central Nervous System Neoplasms
2
Spinal Cord Neoplasms
1
Somatostatinoma
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
90 days
×
Clear all
No trials found.